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INTRODUCTION
Donor-derived cytotoxic T-cells (CTLs) directed at recip-
ients’ minor histocompatibility antigens (mHags) are impor-
tant effector cells in the graft-versus-leukemia effect after
HLA-matched–mHag-mismatched stem cell transplantation
(SCT) [1-4]. Although several mHags are ubiquitously
expressed, the expression of mHags HA-1 and HA-2 is
restricted to the cells of hematopoietic lineage [5-8]. HLA-
A2–restricted HA-1/HA-2–specific CTLs effectively lyse
hematopoietic cells including leukemic cells and their clono-
genic precursors but do not affect nonhematopoietic cells such
as skin ﬁbroblasts, keratinocytes, and epithelial and endothelial
cells [5]. Thus, after an HLA-matched–mHag–HA-1/HA-2–
mismatched SCT, in vitro generated HA-1/HA-2–specific
CTLs from the SC donors may serve as therapeutic tools to
induce the graft-versus-leukemia effect with a low risk of
graft-versus-host disease (GVHD). Previously, we and others
demonstrated the in vitro generation of HA-1/HA-2–speciﬁc
CTLs from healthy SC donors using dendritic cells (DCs)
pulsed with HA-1/HA-2 peptides as antigen presenting cells
(APCs) [9-11]. This procedure, however, requires at least
6 weeks of in vitro culture. Moreover, we observed that induc-
tion of HA-1–speciﬁc CTLs from some SC donors was inefﬁ-
cient under GMP (good manufacturing practice) conditions
(unpublished observations). Therefore, we investigated an
alternative strategy for the in vitro induction of HA-1 CTLs.
Efficient Induction of Minor Histocompatibility Antigen
HA-1–Specific Cytotoxic T-Cells Using Dendritic Cells
Retrovirally Transduced with HA-1–Coding cDNA
Tuna Mutis,1 Kamran Ghoreschi,2 Ellen Schrama,1 Janine Kamp,1 Mirjam Heemskerk,3
J. H. Frederik Falkenburg,3 Martina Wilke,1 Els Goulmy1
1Department of Immunohematology and Blood Transfusion, Leiden University Medical Center, Leiden, 
The Netherlands; 2Department of Dermatology, University of Munich, Munich, Germany; 
3Department of Hematology, Leiden University Medical Center, Leiden, The Netherlands
Correspondence and reprint requests: Tuna Mutis, MD, PhD, Leiden University Medical Center, Department 
of Immunohematology and Blood Transfusion, E3-Q, Albinusdreef 2, 2333 ZA Leiden, The Netherlands 
(e-mail: t.mutis@lumc.nl).
Received February 11, 2002; accepted May 24, 2002
ABSTRACT
Cytotoxic T-cells (CTLs) specific for the hematopoietic system–restricted minor histocompatibility antigen
(mHag) HA-1 efficiently lyse HA-1–positive leukemic cells without affecting nonhematopoietic cells. HA-1–specific
CTLs are thus potential tools for adoptive immunotherapy of relapsed leukemia after HLA-matched–HA-1–
mismatched stem cell transplantation (SCT). In vitro generation of HA-1–specific CTLs from SC donors is possi-
ble using dendritic cells (DCs) pulsed with synthetic HA-1 peptide as stimulator cells. However, this approach
requires at least 6 weeks of in vitro culturing under GMP (good manufacturing practice) conditions. Our data
show that in vitro induction of HA-1–specific CTLs is more rapid with the use of DCs that are retrovirally trans-
duced with the HA-1 complementary DNA. Retrovirally transduced DCs showed functional and long-term stable
expression of the HA-1 CTL epitope in primary CTL cultures. In 4 SC donors, HA-1–transduced DCs induced
HA-1– specific CTLs in 14 to 21 days. The in vitro–generated CTL lines contained 6% to 9% T-cells that stained
brightly with tetrameric HLA-A2/HA-1 peptide complexes (HA-1A2 tetramer) and showed significant lysis of HA-
1+ leukemic cells. The CTL induction procedure using peptide-pulsed DCs was less effective and required 28 to
35 days of T-cell culture. Thus, sustained presentation of mHag HA-1 by retrovirally transduced DCs facilitates
the in vitro induction of HA-1–specific CTLs.
KEY WORDS
Minor histocompatibility antigen HA-1 • Cytotoxic T-cells • Dendritic cells • Antigen
presentation • Retroviral gene transfer • Immunotherapy
Biology of Blood and Marrow Transplantation 8:412-419 (2002)
© 2002 American Society for Blood and Marrow Transplantation ASBMT
Induction of HA-1–Specific CTLs by HA-1–Transduced DCs
413B B & M T
In recent studies, DCs were genetically modified to
endogenously express the tumor-associated antigens (TAAs)
for the induction of tumor-speciﬁc immunity [12-18]. Con-
stitutive expression of the TAAs in genetically modiﬁed DCs
may not only result in effective antigen presentation to
CTLs but may also allow recognition of the tumor antigen
by HLA class II–restricted helper T-cells that provide help
for the generation and maintenance of CTLs [19-21].
In this study, we analyzed the efﬁcacy of the generation
of HA-1–speciﬁc CTLs with DCs that are genetically engi-
neered to express the HA-1 CTL epitope. A 358–base pair
(bp) complementary DNA (cDNA) containing the genetic
information for the HA-1 CTL epitope was introduced to
CD34+ DC progenitors using a retroviral delivery system.
CD34+ cells were differentiated into DCs by culturing with
appropriate cytokines and were used to induce HA-1–speciﬁc
CTLs from 6 HLA-A2+ HA-1– SC donors. In 2 of these
donors, HA-1–speciﬁc CTLs were induced in parallel with
peptide-pulsed DCs to compare the efﬁcacy of both CTL
induction systems.
MATERIALS AND METHODS
Construction of the Retroviral Vector Containing the
HA-1–Coding cDNA
The 358-bp cDNA encoding the HA-1 CTL epitope
VLHDDLLEA was inserted into the pLZRS-polylinker-
IRES-GFP retroviral vector. This vector contains the
puromycin resistance gene to allow the selection of pack-
aging cells that episomally express the retroviral vector. In
addition, the vector contains the green fluorescent protein
(GFP) as a marker gene and an internal ribosomal entry
site (IRES) between the marker gene and the gene of
interest, which ensures independent coexpression of both
transgenes [22]. The HA-1–encoding cDNA was cleaved
from the pCDNA–HA-1 plasmid as an XbaI/BamHI frag-
ment, ligated into the pBluescript II SK+, excised from the
latter vector as an EcoRI/NotI fragment, and cloned into
the EcoRI/NotI sites of the polylinker of the pLZRS-
BMN-IRES-GFP vector. The resulting vector is desig-
nated as LZRS-BMN-HA-1-IRES-GFP (HA-1 vector).
The HA-1 vector was transfected into a Phoenix-A pack-
aging cell line using the calcium phosphate method as
described by the manufacturer (Life Technologies, Breda,
The Netherlands). Transfected cells were cultured in
Iscoves modified Dulbecco’s medium (IMDM) with 10%
fetal calf serum (FCS). At day 2, puromycin (2 mg/mL)
was added to select the transfected packaging cells that
expressed the puromycin resistance gene that was present
in the retroviral vector. After 10 to 14 days, 6 × 106
puromycin-resistant cells were plated per 10-cm petri dish
(Becton Dickinson, San Jose, CA) in 10 mL complete
medium without puromycin. After 48 hours, the retroviral
supernatant was harvested, centrifuged, and frozen in 1
mL aliquots at –70°C. The HA-1– Epstein-Barr
virus–transformed B cell lines (EBV-LCLs) and HeLa cells
transduced with HA-1 vector induced significant HA-
1–specific proliferation and tumor necrosis factor (TNF)-α
release and were lysed by HA-1–specific CTL clones
demonstrating the proper expression of the HA-1 CTL
epitope in transduced cells (data not shown).
Isolation of CD34+ Dendritic Cell Progenitors,
Retroviral Transduction, and DC Culture
Bone marrow aspirate or SC-mobilized blood was col-
lected from donors who had given informed consent. CD34+
cells were isolated using an immunomagnetic-bead cell-
selection system (Clinimacs; Miltenyi Biotech, Bergisch
Gladbach, Germany). The CD34+ cells were cultured in
IMDM and 10% autologous heparinized plasma at a concen-
tration of 3 × 105 cells/mL in 24-well ﬂat-bottomed tissue
culture plates (Costar; Corning, Acton, MA) in the presence
of a cytokine mix consisting of granulocyte-macrophage
colony-stimulating factor (GM-CSF), 100 ng/mL (Gen-
zyme, Leuven, Belgium); TNF-α, 2 ng/mL (Genzyme); and
FLT3 ligand (FLT3-L), 100 ng/mL (R&D Systems, Min-
neapolis, MN). At day 2, the cells were transduced with
retroviral supernatants with the use of recombinant human
ﬁbronectin fragments CH-296 (Retronectin; Takara, Otsu,
Japan) as described elsewhere [22]. Twenty-four hours after
transduction, the CD34+ cells were transferred into tissue-
culture plates and further cultured in IMDM supplemented
with 10% autologous plasma and the cytokine mix. On day
4, this medium was refreshed with the addition of interleukin
(IL)-4 (Genzyme), 500 U/mL. After 10 to 12 days, the retro-
virally transduced DCs with HA-1 cDNA (HA-1–transduced
DCs) were phenotypically analyzed and used as stimulator
cells. The percentage of GFP+ cells was measured at days 2
and 10 to determine the transduction efﬁciency and stability
of the transgene.
Monoclonal Antibodies, HA-1A2 Tetramers, and
Phenotype Analysis
Fluoroscein isothiocyanate– or PE-conjugated mono-
clonal antibodies (MoAbs) against immunoglobulin (Ig)G1,
IgG2, HLA-DR, CD1a, CD3, CD4, CD8, CD11c, CD14,
CD16, CD19, CD20, CD80, and CD86 (Becton Dickinson)
and CD83 (Immunotech, Marseille, France) were used at
appropriate dilutions. The PE-conjugated HA-1A2 tetramers
were generated as described previously [23]. For the pheno-
typical analysis, the cells were surface labeled with MoAbs
and/or with HA-1A2 tetramers for 20 minutes at 37°C. The
cells were then fixed with 1% paraformaldehyde and ana-
lyzed on a Becton Dickinson FACS-calibur ﬂow cytometer.
Data were analyzed using CellQuest (Becton Dickinson)
and WinMDI (version 2.8 J. Trotter; Scripps Research Insti-
tute, La Jolla, CA) software.
HA-1 Peptide
The HA-1 peptide was synthesized using a semiauto-
matic multiple peptide synthesizer according to the reported
sequence VLHDDLLEA [24]. The purity of the peptide
was >95%, as analyzed by reverse-phase high-pressure liq-
uid chromatography.
In Vitro Induction of HA-1–Specific CTLs from HA-1–
SC Donors
Responder peripheral blood mononuclear cells (PBMCs)
(20-30 × 106 cells) from HLA-A2+ HA-1– SC donors were
stimulated with autologous HA-1–transduced DCs at a
responder-to-stimulator ratio of 8:1 in 24-well tissue culture
plates containing 1 mL/well IMDM, 10% autologous
plasma, 6 IU/mL IL-2, 1U/mL IL-12 (R&D Systems). On
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day 5, 60 IU/mL of IL-2 was added. On day 7, the CTLs
were depleted of CD4+ T-cells and restimulated (first res-
timulation) with HA-1–transduced DCs at a responder-to-
stimulator ratio of 8:1. After 24 hours and then every other
3 days, 120 IU/mL IL-2 was added. On day 14, the CTLs
were restimulated (second restimulation) using (1) HA-1–
transduced DCs (CTL#2, CTL#4), (2) HA-1 peptide–pulsed
DCs (CTL#3), or (3) HA-1–transduced EBV-LCLs (CTL#1).
From day 21 on, all CTLs were restimulated with peptide-
pulsed (1 mg/mL) monocytes. The CTLs were analyzed
with HA-1A2 tetramers and for HA-1–specific cytotoxic
activities prior to each restimulation.
Target Cells, CTL Clones
Target Cells. EBV-LCLs were cultured in IMDM, 10%
FCS. Phytohemagglutinin (PHA)-activated T-cell blasts
(PHA blasts) were induced by stimulation of PBMCs with
0.5% PHA in RPMI, 15% human serum, and 120 IU/mL
IL-2. On day 7, the PHA blasts were harvested and used as
target cells.
CTL Clones. The mHag HA-1–speciﬁc CTL clone 3HA15
and the control mHag HA-3–specific CTL clone 5HO11
were previously isolated from the PBMCs of GVHD patients
who received HA-1– or HA-3–mismatched SCT [3].
T-Cell Proliferation Assays
Responder T-cells (1-2 × 104 cells/well) were cocultured
with irradiated stimulator cells (2-10 × 104 cells/well) in
96-well flat-bottomed microtiter plates for 72 hours in
200 µL of RPMI supplemented with 15% human serum.
Sixteen hours before harvesting, 0.5 Ci of 3H-thymidine was
added. The 3H-thymidine incorporation was determined by
liquid scintillation counting. The results are expressed as the
mean of triplicate cultures. The standard error of the mean
(SEM) of the results did not exceed 15%.
Cell-Mediated Lympholysis Assay
51Cr-labeled target cells (3000 cells/well) were incubated
with serial dilutions of effector cells in 96-well round-
bottomed microtiter plates (Costar 3799) at 37°C. After
4 hours, the cell-free supernatants were harvested for
γ counting. The percent speciﬁc lysis was calculated as fol-
lows: % speciﬁc lysis = (experimental release – spontaneous
release)/(maximal release – spontaneous release) × 100%.
Spontaneous release and maximal release are the
chromium release of target cells in culture medium alone
and in culture medium containing 1% triton-X 100, respec-
tively. The SEM of the results did not exceeded 5%. If the
SEM of the results exceeded 5%, the results were discarded.
Statistical Analysis
The effects of FLT-3 ligand on transduction efﬁciency,
cell viability, and cell yields were tested using a paired t test.
The Mann-Whitney test was used to test the signiﬁcance of
the difference in generation of HA-1–speciﬁc CTLs using
HA-1–transduced DCS compared with that using peptide-
pulsed DCs. The results are expressed as 2-tailed P values
within 95% conﬁdence intervals.
RESULTS
Retroviral Transduction of CD34+ Cells
Bone marrow or SC-mobilized blood-derived CD34+
cells, cultured with the different cytokine cocktails to induce
DC differentiation, were transduced at day 1, 2, or 3 of cul-
ture (Table 1). Day 2 was the optimal day of transduction,
with mean transduction rates of 26%. Addition of FLT-3
ligand in the cytokine cocktail significantly increased the
mean transduction efficiency from 26% to 37% (P < .05)
(Table 1). FLT-3 ligand also signiﬁcantly increased the cell
viability and cell yields (P < .05). After 12 to 13 days of DC
culture, the total number of cells increased 10- to 15-fold.
During this period, the percentage of GFP+ cells remained
unchanged, demonstrating the stability of the transgene
(Table 1). CD34+ cells derived from both bone marrow and
SC-mobilized blood showed equal transduction efﬁciencies
(data not shown).
Immunophenotype of Retrovirally Transduced DCs
Retrovirally transduced cells were analyzed for lineage
and cell activation markers (Table 2, Figure 1A) at day 13 of
DC culture. Neither GFP+ (transduced) nor GFP– (untrans-
duced) cells in the cultures expressed the cell lineage mark-
ers CD3, CD14, CD19, CD56, or CD66. HLA-DR was
expressed on 83% (±16%) of the transduced, and on 78%
Table 1. Retroviral Transduction Efﬁciency of CD34+ DC Precursor Cells*
Retroviral % GFP
+ Cells (Range)
Cytokines Transduction Day Day 6-7 Day 12-13
GMCSF+ TNF-α 1 11 (7-12) 10 (8-13)
2 26 (22-31) 25 (20-31)†
3 23 (21-24) 24 (20-26)
GMCSF+ TNF-α + FLT3-L 1 13 13
2 37 (32-41) 32 (29-38)†
3 24 (22-28) 26 (21-27)
*CD34+ cells derived either from bone marrow or from stem
cell–mobilized peripheral blood were cultured with the indicated
cytokines and transduced at the indicated days of culture. The GFP+
cells at day 6-7 and day 12-13 of the cultures were determined by
FACS analysis. 
†The statistical difference between the indicated values is signifi-
cant (P < .05) in paired t test.
Table 2. Immunophenotype of Retrovirally Transduced DCs*
Surface Molecule % GFP+ Cells % GFP– Cells
HLA-DR 83 ± 16 78 ± 9
CD1a 74 ± 17 67 ± 6






*Retrovirally transduced DCs were analyzed for the surface expres-
sion markers on day 13 of DC culture. Data are representative of
5 independent DC cultures.
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(±9%) of the nontransduced cells, indicating that approxi-
mately 80% of both the transduced and the nontrans-
duced cell fractions comprised HLA-DR–positive, lineage
marker–negative DCs. Bright staining with the monocyte/
DC marker CD11c showed on 81% of GFP+ and 74% of
GFP– cells. CD1a expression was similar on GFP+ and
GFP– cells, 67% and 74%, respectively. The expression lev-
els of HLA-DR, CD80, and CD86 were moderate or low on
both transduced (Figure 1A) and nontransduced DCs (data
not shown). Furthermore, little or no expression of CD83
on either GFP+ or GFP– cells indicated that both transduced
and nontransduced DCs showed an immature DC pheno-
type (Figure 1A).
Long-term Persistence of Retrovirally Transduced
DCs in the CTL Cultures
To estimate whether retrovirally transduced DCs can
express the HA-1 vector for prolonged periods in the CTL
cultures, the HA-1–transduced DCs were cocultured with
autologous PBMCs and analyzed at different days of cul-
ture. The HA-1–transduced GFP+ DCs were detected in the
cultures for up to 7 days (Figures 1B and 1C). During this
period, the transduced DCs retained their immature pheno-
type (Figure 1B and 1C). In control assays, retrovirally
transduced DCs significantly up-regulated HLA-DR,
CD80, and CD86 and induced CD83 after 48 hours of cul-
ture on a CD40-ligand–expressing fibroblast line (Figure
1D), indicating that the intrinsic maturation pathway of
retrovirally transduced DCs was functional but was not trig-
gered by coculture with autologous PBMCs.
Efficient Presentation of the mHag HA-1 CTL
Epitope by HA-1–Transduced DCs
To estimate the antigen-presenting capacity, HA-1–
transduced DCs were used to stimulate the proliferation of
the HA-1–speciﬁc CTL clone 3HA15 (Figure 2). Nontrans-
duced DCs pulsed with 1 µg/mL HA-1 peptide were used as
control APCs. The HA-1–speciﬁc CTL clone 3HA15 was
stimulated strongly by HA-1–transduced DCs and by peptide-
pulsed DCs in a similar fashion. The mHag HA-3– speciﬁc
CTL clone 5HO11, which was used as negative control, was
Figure 1. Immunophenotype of retrovirally transduced DCs. Retrovirally transduced DCs were stained with PE-conjugated MoAbs speciﬁc for
HLA-DR, CD80, CD86, and CD83. Histograms represent the expression of markers on GFP+ cells. Similar results were obtained by putting the
gates on GFP+, HLA-DR+ CD14– cells. A, Retrovirally transduced DCs on day 12 of DC culture, prior to culturing with responder PBMCs. B,
Retrovirally transduced DCs on day 2 of coculturing with responder PBMCs. C, Retrovirally transduced DCs on day 7 of coculturing with respon-
der PBMCs. D, Retrovirally transduced DCs cocultured for 48 hours with CD40-L transfected ﬁbroblasts.
Figure 2. Presentation of the HA-1 CTL epitope by HA-1–trans-
duced DCs. Serial dilutions of HA-1–transduced DCs with 25% trans-
duction efﬁciency were used to stimulate the proliferation of the HA-
1–speciﬁc CTL clone 3HA15 (H17009) and the control HA-3–speciﬁc CTL
clone 5HO11 (). Peptide-pulsed (1 mg/mL) DCs () and nontrans-
duced DCs () were also used as control APCs.
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not stimulated at all, showing that retrovirally transduced
DCs induce only speciﬁc T-cell proliferation.
Efficient Induction of HA-1–Specific CTLs by 
HA-1–Transduced DCs
HA-1–transduced DCs were used as stimulator cells to
stimulate PBMCs from 6 HLA-A2+, HA-1– healthy SC
donors. The transduction efficiencies varied from 11% to
35% (Figure 3A). Independent of the variable transduction
efficiencies, HA-1–specific CTLs were induced from
4 donors after 1 (donor #1) or 2 rounds (donors #2, #3, and
#4) of restimulation with HA-1–transduced DCs. The
CTLs showed high avidity for the HLA-A-2/HA-1 ligand as
demonstrated by the significant lysis of HA-1 peptide-
pulsed EBV-LCLs and EBV-LCLs and leukemic (acute
lymphoblastic leukemia) cells that naturally express the
HLA-A2/HA-1 ligand. Analysis with the HA-1A2 tetramers
revealed that 6% to 9% of the lymphocytes in the cultures
were HA-1–speciﬁc CTLs (Figures 3B and 3C).
From 2 other donors, CTLs could be generated neither
with HA-1–transduced DCs nor with peptide-pulsed DCs
(data not shown).
Comparison of HA-1–Transduced and Peptide-Pulsed
DCs for the Induction of HA-1–Specific CTLs
In parallel with the HA-1–transduced DCs, peptide-
pulsed DCs were used to generate HA-1–speciﬁc CTLs in
donors #2 and #3 (Figure 4A). For the latter strategy, the
DCs were pulsed with 1 µg/mL peptide for 2 hours in
serum-free medium, conditions that had previously been
found to be optimal [10].
In donor #2, HA-1–transduced DCs induced strong HA-
1–speciﬁc cytotoxic activity within 21 days. The CTL culture
contained 8% HA-1A2 tetramer+ cells. In contrast, peptide-
pulsed DCs induced a weak HA-1–speciﬁc CTL response,
with only 2% HA-1A2 tetramer+ cells at day 21. At day 28,
after another round of stimulation, CTLs induced with peptide-
pulsed DCs also showed signiﬁcant HA-1–speciﬁc cytotoxic
activity and contained 13% HA-1A2 tetramer+ cells.
In donor #3, HA-1–transduced DCs induced strong
HA-1–speciﬁc CTLs within 21 days. The culture contained
9% HA-1A2 tetramer+ cells. Peptide-pulsed DCs, however,
failed to induce an HA-1–speciﬁc CTL response at day 21.
The CTL culture contained less than 1% HA-1A2 tetramer+
cells. At day 28, the HA-1A2 tetramer+ cells increased up to
Figure 3. Induction of HA-1–speciﬁc CTLs by HA-1–transduced DCs. CD34+ cells were isolated from bone marrow (donor #1) or from stem
cell–mobilized peripheral blood (donors #2, #3, and #4) of HLA-A2+ HA-1– donors. CD34+ cells were transduced at day 2. A, The transduction efﬁ-
ciency and the GFP expression levels of DCs at day 12. The GFP+ cells were negative for lineage markers and contained 78%, 82%, 87%, and 76%
HLA-DR+ DCs for donors #1, #2, #3, and #4, respectively. B, The cytotoxic activity of CTLs measured at day 21. C, Immunostaining of CTLs with
CD8 antibodies plus HA-1A2 tetramers.
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Figure 4. Comparison of HA-1–transduced and peptide-pulsed DCs for the induction of HA-1–speciﬁc CTLs. A, In donors #2 and #3 the HA-1–
speciﬁc CTL cultures were simultaneously induced with retrovirally transduced DCs and with peptide-pulsed DCs. The percent speciﬁc lysis levels
of the indicated target cells are presented on the left axes and the percentages of HA-1A2 tetramer+ T-cells in the cultures are presented on the right
axes. The percent lysis levels are shown only for the highest effector target ratio of 30:1. B, Comparison of HA-1–speciﬁc CTLs generated by peptide-
pulsed and HA-1–transduced DCs from different individuals. For all CTLs, the day of culture during which HA-1A2 tetramer+ cells reached 5% or
more are shown.
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4% but the HA-1–specific cytotoxic activity of the CTLs
remained poor. Neither the cytotoxic activity nor the per-
centage of tetramer+ cells in the peptide-induced CTL line
could be further improved by repeated rounds of restimula-
tion (data not shown).
In addition, we determined the day of culture on which
the HA-1A2 tetramer+ cells reached 5% or more in several
other in vitro–induced HA-1–speciﬁc CTL lines. Compari-
son of the CTLs induced with HA-1–transduced DCs (n = 4)
with CTLs induced with peptide (n = 8) revealed a signiﬁ-
cant difference in favor of HA-1–transduced DCs for the
induction time of HA-1–speciﬁc CTLs (Figure 4B).
DISCUSSION
In this study we show that DCs that are transduced with
the cDNA coding for the HA-1 CTL epitope are efﬁcient
APCs for the in vitro induction of mHag HA-1–specific
CTLs from HA-1– SC donors. HA-1–transduced DCs trig-
ger HA-1–speciﬁc CTL responses with more rapid kinetics
than the CTLs induced with peptide-pulsed DCs.
In various model systems and in clinical studies, peptide-
pulsed DCs were successfully used to induce tumor-speciﬁc
T-cell responses [25-34]. Earlier, we showed the in vitro gen-
eration of mHag HA-1/HA-2–speciﬁc CTLs from unprimed
SC donors with the use of DCs pulsed with synthetic HA-1/
HA-2 peptides [9,10]. However, a major drawback of the
peptide-pulsing strategy is the “peptide dose.” Optimal
induction and expansion of high-avidity CTLs with peptide-
pulsed DCs requires a critical dose of peptide that needs to
be determined carefully. It has been shown that peptide con-
centrations that are too high can induce low-avidity CTLs or
may even deplete T-cell responses by induction of anergy or
by activation-induced cell death [35,36]. On the other hand,
peptide concentrations that are too low may not induce T-cell
responses at all. In line with these observations, our previous
studies revealed that HA-1 peptide optimally induces CTLs
within a narrow window, with 1 µg/mL being the optimal
dose. Fivefold higher or lower concentrations were detri-
mental [10]. Another drawback of peptide-pulsing strategy is
the loss of peptides from the DC surface. Because the pre-
cursors of both CD4+ and CD8+ T-cells require sustained
antigen presentation to become activated, it may be possible
that synthetic peptides may dissociate from the major histo-
compatibility complex molecules before fully activating the
unprimed T-cells. An advantage of introduction of tumor
antigens in DCs is that the antigens can be continuously pre-
sented to T-cells. We therefore chose the retroviral gene
delivery system because it readily transduces CD34+ cells and
allows stable expression of the transgene during the DC dif-
ferentiation and CTL culture periods.
In our assays, HA-1–transduced DCs persisted in the in
vitro CTL cultures for at least 7 days and induced HA-1–
speciﬁc CTLs more rapidly than DCs pulsed with the opti-
mum peptide dose. Thus, our results suggest that sustained
presentation of HA-1 CTL epitope on HA-1–transduced
DCs is an important factor that facilitates the in vitro genera-
tion of HA-1–speciﬁc CTLs.
Our results also show that strong HA-1–speciﬁc T-cell
responses can be generated with relatively low transduction
efficiencies. We established a maximum of 40% transduc-
tion efﬁciency, with a mean efﬁciency of 20%. However, we
have observed that strong HA-1–speciﬁc CTLs can be gen-
erated even with 11% transduction efﬁciency. Thus, retrovi-
rally transduced DCs efﬁciently present the CTL epitopes
to unprimed T-cells. Therefore, high transduction efﬁcien-
cies are not per se necessary for the induction of relevant
CTL responses.
A possible advantage of expression of the target antigen
in DCs may be the activation of antigen-specific CD4+
T-helper cells [37]. However, we have as yet no evidence
that the mHag HA-1 segment inserted in DCs contains an
HLA class II–restricted T-cell epitope. The CD4+ T-cells
isolated from our in vitro cultures did not show HA-1 speci-
ﬁcity (data not shown). The lack of speciﬁc or nonspeciﬁc
CD4 help may hamper the efficient generation of HA-1–
speciﬁc CTLs and may be the reason why we could not gen-
erate HA-1–speciﬁc CTLs from 2 SC donors using either
peptide-pulsed or HA-1–transduced DCs.
In conclusion, our results show the rapid induction of
HA-1 CTLs by HA-1–transduced DCs, probably due to
sustained antigen presentation to unprimed CTL precur-
sors. Retrovirally transduced DCs can thus function as ade-
quate APCs for the in vitro induction of HA-1–specific
CTLs for adoptive immunotherapy and for vaccination of
the HA-1– SC donors or HA-1–positive SC recipients who
undergo HA-1–mismatched SCT [38].
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